US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Xtrackers Nifty 500 India ETF

23.15

-0.0133-0.06%

Volume:494

Turnover:11.43K

Market Cap:4.63M

PE:- -

High:23.15

Open:23.12

Low:23.12

Close:23.16

52wk High:27.40

52wk Low:20.52

Shares:200.00K

Float Shares:200.00K

Volume Ratio:0.63

T/O Rate:0.25%

Dividend:0.08

Dividend Rate:0.34%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Splash Beverage Group Expands CannEpil® Platform into Veterinary Therapeutics, Establishing Second FDA-Regulated Pharmaceutical Development Program

Dyne Therapeutics receives FDA clearance to initiate DYNE-302 trial

Industrial Minerals pivots into gold with Laverton portfolio acquisition

Urban Company Sets Board Meeting and Earnings Call for Q1 FY2027 Results

Kelun Pharmaceutical's Subsidiary Kelun-Biotech Gets Approval for Clinical Trial of Novel Dual-Load ADC Drug SKB565

Press Release: NeOnc Technologies Appoints Strategy and Finance Executive Nasim Shomali to Its Board of Directors

Neumora Therapeutics Plans Q4 IND Filing for Obesity Drug After Repeat Toxicology Study

MT Newswires Live

Humacyte Announces FDA Acceptance of IND for First-In-Human Clinical Study of CTEV for Coronary Artery Bypass Grafting

RBI Intervention Boosts Rupee, Posting Biggest Single-Day Gain in Over a Month

Traders Reveal Central Bank Sold US Dollars in Foreign Exchange Markets to Support the Rupee

Oil Prices Decline, Indian Stock Market Rises for First Time in Six Days

Celltrion Submits Dual-Part EMA Application for Subcutaneous Rheumatoid Arthritis Drug

MT Newswires Live

Celltrion Submits South Korean IND for Subcutaneous Rheumatoid Arthritis Drug

MT Newswires Live

Indian Rupee Strengthens as Central Bank Intervenes in Onshore and Offshore Forex Markets

Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease

YD Bio and EG BioMed Conclude Successful Exhibition at BIO Asia-Taiwan 2026, Highlighting Innovations in Ophthalmology, Oncology Diagnostics, and Clinical Services

Industrial Minerals calls crucial shareholder vote on Galleon Metals acquisition

Silo Pharma Advances Growth Platforms for AI Agent Commercialization and Lead PTSD Drug Program

Calidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value Drivers

Is HBM Holdings (SEHK:2142) Fully Valued After Its Asthma IND Approval?

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/IND/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IND","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IND\",,,,,undefined,":{"symbol":"IND","market":"US","secType":"STK","nameCN":"Xtrackers Nifty 500 India ETF","latestPrice":23.145,"timestamp":1788206400000,"preClose":23.1583,"halted":0,"volume":494,"delay":0,"changeRate":-0.0005743081314259241,"floatShares":200001,"shares":200001,"eps":0,"marketStatus":"Pre-Mkt","change":-0.0133,"latestTime":"09-01 06:01:37 EDT","open":23.115,"high":23.145,"low":23.115,"amount":11430,"amplitude":0.001295,"askPrice":24,"askSize":19,"bidPrice":9.31,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1788269400000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":23.145,"sharesOutstanding":200001,"nav":23.107,"aum":4621406.79,"dividendRate":0.003409,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":23.115,"preClose":23.145,"latestTime":"16:10 EDT","volume":7,"amount":162.015,"timestamp":1788207004404,"change":-0.03,"changeRate":-0.001296,"amplitude":0},"volumeRatio":0.6283389809433055},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IND\",,,,,undefined,":{"symbol":"IND","floatShares":200001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.6283389809433055,"shares":200001,"dividePrice":0.0789,"high":23.145,"amplitude":0.001295,"preClose":23.1583,"low":23.115,"week52Low":20.515,"pbRate":"--","week52High":27.4,"institutionHeld":0,"latestPrice":23.145,"committee":0.680672,"eps":0,"divideRate":0.003409,"volume":494,"delay":0,"ttmEps":0,"open":23.115,"prevYearClose":24.78,"prevWeekClose":23.1583,"prevMonthClose":23.145,"prevQuarterClose":22.88,"fiveDayClose":23.065,"twentyDayClose":23.01,"sixtyDayClose":22.2234},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IND\",params:#limit:5,,,undefined,":[{"date":"2026-06-18","symbol":"IND","amount":0.07775,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-18","defaultRemindTime":1781789400000,"name":"Xtrackers Nifty 500 India ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-26","payableDate":"2026-06-18","currency":"USD","dateTimestamp":1781755200000,"payDate":"2026-06-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IND\",market:\"US\",,,undefined,":[{"executeDate":"2026-06-18","recordDate":"2026-06-18","paymentDate":"2026-06-26","value":0.07775,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IND\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IND\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2655895044","title":"Splash Beverage Group Expands CannEpil® Platform into Veterinary Therapeutics, Establishing Second FDA-Regulated Pharmaceutical Development Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2655895044","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655895044?lang=en_us&edition=fundamental","pubTime":"2026-07-29 20:30","pubTimestamp":1785328200,"startTime":"0","endTime":"0","summary":"Expansion broadens CannEpil into veterinary therapeutics as Splash advances its cannabinoid pharmaceutical development platformFORT LAUDERDALE, Fla., July  29, 2026  (GLOBE NEWSWIRE) -- Splash Beverag","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/29/3335211/0/en/Splash-Beverage-Group-Expands-CannEpil-Platform-into-Veterinary-Therapeutics-Establishing-Second-FDA-Regulated-Pharmaceutical-Development-Program.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4185","BK4539","LABU","LU1201861165.SGD","LU0963586101.USD","IND","BK4588","CBD","LU0648000940.SGD","IEIH","BK4007","LNGR","BK4139","LU2324357040.USD","LENZ","BK4113","BK4585","LU0130103400.USD","THC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654009072","title":"Dyne Therapeutics receives FDA clearance to initiate DYNE-302 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2654009072","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654009072?lang=en_us&edition=fundamental","pubTime":"2026-07-28 19:40","pubTimestamp":1785238813,"startTime":"0","endTime":"0","summary":"Dyne Therapeutics (DYN) announced that it has received clearance from the FDA for its IND application to initiate a Phase 1 clinical trial for DYNE...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/dyne-therapeutics-receives-fda-clearance-to-initiate-dyne-302-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/dyne-therapeutics-receives-fda-clearance-to-initiate-dyne-302-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DYN","GDOC","IDNA","MEDX","LABU","NVIB","BK4588","BK4585","BK4139","BK4134","HYLG","IND","BK4505","DYNE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654738930","title":"Industrial Minerals pivots into gold with Laverton portfolio acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2654738930","media":"TIPRANKS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654738930?lang=en_us&edition=fundamental","pubTime":"2026-07-28 12:57","pubTimestamp":1785214655,"startTime":"0","endTime":"0","summary":"Industrial Minerals Limited ( ($AU:IND) ) has provided an update. Industrial Minerals Ltd has agreed to acquire the Laverton Gold Portfolio in West...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/industrial-minerals-pivots-into-gold-with-laverton-portfolio-acquisition?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/industrial-minerals-pivots-into-gold-with-laverton-portfolio-acquisition?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OUNZ","DBC","SGUmain","IND","GDX","GLTR","FGDL","518880","GCmain","BTGD","JDST","CEF","PICK","IAU","RING","SHNY","XME","GLDM","GOAU","UYM","BEGS","AAAU","UGL","GOLY","159934","DGP","GLD","IAUI","SGDM","PPI","DULL","DUST","JNUG","PHYS","GLL","MTX","DZZ","MGCmain","GDXD","NUGT","SGOL","GDXY","1OZmain","GBUG","IAUM","GDXJ","BAR","USG","SGCmain","GDXU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654047418","title":"Urban Company Sets Board Meeting and Earnings Call for Q1 FY2027 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2654047418","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654047418?lang=en_us&edition=fundamental","pubTime":"2026-07-28 03:14","pubTimestamp":1785179656,"startTime":"0","endTime":"0","summary":"An update from Urban Company Limited ( ($IN:URBANCO) ) is now available. Urban Company Limited, a listed Indian marketplace for home and personal s...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/urban-company-sets-board-meeting-and-earnings-call-for-q1-fy2027-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/urban-company-sets-board-meeting-and-earnings-call-for-q1-fy2027-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FLIN","BK4585","INDA","SMIN","INDY","SCIN","EPI","IND","BK4523","PIN","INDL","BK4588","NFTY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142348091","title":"Kelun Pharmaceutical's Subsidiary Kelun-Biotech Gets Approval for Clinical Trial of Novel Dual-Load ADC Drug SKB565","url":"https://stock-news.laohu8.com/highlight/detail?id=1142348091","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142348091?lang=en_us&edition=fundamental","pubTime":"2026-07-27 22:20","pubTimestamp":1785162017,"startTime":"0","endTime":"0","summary":"Sichuan Kelun Pharmaceutical Co.,Ltd. (SZ: 002422) has announced that its controlling subsidiary, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., received a clinical trial approval notice from the...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBBQ","ADC","BK4080","BK0060","IND","LU1979443071.USD","IBBJ","LU2148510915.USD","NETL","PSYK","BK0239","002422","BMED","LU1064131003.USD","LU1934453819.USD","MDTX","LU1064130708.USD","BK4231"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654048668","title":"Press Release: NeOnc Technologies Appoints Strategy and Finance Executive Nasim Shomali to Its Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2654048668","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654048668?lang=en_us&edition=fundamental","pubTime":"2026-07-27 21:00","pubTimestamp":1785157200,"startTime":"0","endTime":"0","summary":"CALABASAS, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (\"NeOnc\" or the \"Company\"), a multi-Phase 2 clinical-stage biopharmaceutical company developing no","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","R","03160","NTHI","CNS","IND","BK4022","BK4555","BK4604","BK4585","TM","BK4135","BK4588","BK4007","BK4099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654010397","title":"Neumora Therapeutics Plans Q4 IND Filing for Obesity Drug After Repeat Toxicology Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2654010397","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654010397?lang=en_us&edition=fundamental","pubTime":"2026-07-27 20:21","pubTimestamp":1785154877,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics  said Monday a repeat safety study of its experimental oral obesity drug, NMRA-215, found no unexpected in-life adverse findings, supporting plans to file an investigational new drug application in the fourth quarter of 2026.The company said it repeated the 13-week rat study after an earlier study reported unexpected findings in five of 142 animals.Neumora said an audit found discrepancies that resulted in critical audit observations in how the earlier study was conducted, and the new results, along with previous studies in rats and dogs, suggest the earlier findings were not caused by NMRA-215.Neumora said its preclinical studies showed NMRA-215 produced weight loss as a monotherapy, increased weight loss when used with semaglutide, and improved markers linked to heart and metabolic health.It added that it expects to begin a Phase 1 clinical trial by the end of 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IND","BK4007","NMRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654504582","title":"Humacyte Announces FDA Acceptance of IND for First-In-Human Clinical Study of CTEV for Coronary Artery Bypass Grafting","url":"https://stock-news.laohu8.com/highlight/detail?id=2654504582","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654504582?lang=en_us&edition=fundamental","pubTime":"2026-07-27 20:00","pubTimestamp":1785153600,"startTime":"0","endTime":"0","summary":"– Phase 2a study of CTEV in coronary artery bypass grafting (CABG) is expected to start this quarter – – Progression of CTEV into human study supported by positive preclinical results presented at mul","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/27/3333474/0/en/Humacyte-Announces-FDA-Acceptance-of-IND-for-First-In-Human-Clinical-Study-of-CTEV-for-Coronary-Artery-Bypass-Grafting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","AV","BK4167","IND","CTEV","BK4585","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177586613","title":"RBI Intervention Boosts Rupee, Posting Biggest Single-Day Gain in Over a Month","url":"https://stock-news.laohu8.com/highlight/detail?id=1177586613","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1177586613?lang=en_us&edition=fundamental","pubTime":"2026-07-27 19:48","pubTimestamp":1785152925,"startTime":"0","endTime":"0","summary":"India's central bank intervened heavily in the foreign exchange market on Monday, pushing the rupee to its largest single-day gain in over a month. This move was supported by falling international...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMVP","FLIN","INDE","INCO","NDIA","INDY","SMIN","BK4523","BK4585","TAJX","SCIN","INDA","PIN","INDL","BK4588","IOPP","GIND","IND","FLIBF","NFTY","INQQ","EPI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199292205","title":"Traders Reveal Central Bank Sold US Dollars in Foreign Exchange Markets to Support the Rupee","url":"https://stock-news.laohu8.com/highlight/detail?id=1199292205","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199292205?lang=en_us&edition=fundamental","pubTime":"2026-07-27 17:00","pubTimestamp":1785142830,"startTime":"0","endTime":"0","summary":"Several traders, who requested anonymity, have disclosed that the Indian central bank sold US dollars in both onshore and offshore foreign exchange markets to stabilize the rupee's exchange rate. The...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMVP","BK4585","NDIA","TAJX","INDA","SCIN","IOPP","INCO","BK4523","INDE","FLIBF","IND","ASGM","NFTY","PIN","BK4588","INQQ","INDL","EPI","GIND","UUP","INDY","FLIN","SMIN","UDN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198175648","title":"Oil Prices Decline, Indian Stock Market Rises for First Time in Six Days","url":"https://stock-news.laohu8.com/highlight/detail?id=1198175648","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198175648?lang=en_us&edition=fundamental","pubTime":"2026-07-27 13:01","pubTimestamp":1785128483,"startTime":"0","endTime":"0","summary":"Indian stock markets advanced in early trading, snapping a five-day losing streak, as falling oil prices boosted investor sentiment across Asian markets. The Nifty50 index on the National Stock...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PXJ","BK4523","XC","BK4588","VDE","EEMA","BBEM","DUG","SPXT","UGA","EQLT","GUSH","IMVP","IXC","QEMM","USE","PEMX","INDA","EPI","RWEM","MEM","OIH","WTIU","RAYE","EMXC","XSOE","DEXC","OILK","INCO","INDQ","USOI","ASIA","FLIBF","FEMR","IOPP","INDE","XCEM","AEF","BWET","ERX","PEJ","XXCH","DBC","GIND","DBE","QLVE","DRLL","PIN","BK4550","XCNY","SCIN","EMES","MFEM","SMIN","SCHE","INDZ","UAE","FLIN","OILT","XLEX","NDIA","DRIP","PXE","WEEI","SDOG","GLIN","KEMX","USL","MEMX","AVEM","BKF","DFAE","OILU","SPEM","INQQ","BKEM","DIG","FTXN","VEU","EEMV","BNO","TPOR","XES","BCHI","DBO","SEEM","VOOV","IEO","NFTY","STXE","IND","INDL","TEMX","TAJX","BK4585","INDH","INDY","VEXC","EET","BK4570","TEMR","HEEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653088115","title":"Celltrion Submits Dual-Part EMA Application for Subcutaneous Rheumatoid Arthritis Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2653088115","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653088115?lang=en_us&edition=fundamental","pubTime":"2026-07-24 17:23","pubTimestamp":1784885030,"startTime":"0","endTime":"0","summary":"Celltrion  has submitted applications for its subcutaneous rheumatoid arthritis drug CT-P13 SC  to both the U.S. FDA  and the European Medicines Agency .The company seeks to demonstrate superiority over placebo at 12 weeks in a 296-patient, 52-week global Phase 3 trial, according to a bourse filing on Friday.The subcutaneous formulation, already approved for ulcerative colitis and Crohn's disease in multiple regions, aims to expand its indications and improve patient convenience through a broader treatment population.The company cautions that historically only about 10% of clinical trial drugs ultimately receive marketing approval, and results may fall short of expectations.While both filings share the same clinical design and commercial rationale, the EMA submission explicitly addresses the EU's revised Clinical Trials Regulation requiring separate Part 1  and Part 2  approvals.Both submissions support commercial differentiation through patient diversity, though investors are urged to","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4081","EMA","BK7095","IND","IND.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653700516","title":"Celltrion Submits South Korean IND for Subcutaneous Rheumatoid Arthritis Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2653700516","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653700516?lang=en_us&edition=fundamental","pubTime":"2026-07-24 16:49","pubTimestamp":1784882944,"startTime":"0","endTime":"0","summary":"Celltrion  has filed a Phase 3 IND application with the MFDS for CT-P13 SC  in rheumatoid arthritis, aiming to demonstrate superiority over placebo at 12 weeks.The 296-patient, 52-week trial seeks to expand the drug's approved uses beyond ulcerative colitis and Crohn's disease, leveraging its subcutaneous formulation for patient convenience, according to a bourse filing on Friday.The company cautions that only about 10% of trial drugs ultimately gain marketing approval, and outcomes may not meet expectations.This filing, confirmed on Friday, also supports commercial differentiation and regulatory trends favoring patient diversity, though investors should review all risk disclosures.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182433727","title":"Indian Rupee Strengthens as Central Bank Intervenes in Onshore and Offshore Forex Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=1182433727","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182433727?lang=en_us&edition=fundamental","pubTime":"2026-07-24 12:20","pubTimestamp":1784866849,"startTime":"0","endTime":"0","summary":"Traders, who requested anonymity as they were not authorized to speak publicly, reported that the Reserve Bank of India (RBI) sold US dollars in both the offshore and onshore foreign exchange markets...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INDE","SMIN","ASGM","GIND","NDIA","FLIN","NFTY","EPI","INDL","INDA","INQQ","XCEM","IND","PIN","BK4585","IOPP","SCIN","IUmain","FLIBF","INCO","BK4523","IMVP","GLIN","INDY","BK4588","TAJX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653773779","title":"Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2653773779","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653773779?lang=en_us&edition=fundamental","pubTime":"2026-07-24 04:05","pubTimestamp":1784837100,"startTime":"0","endTime":"0","summary":"-- FDA clearance of the IND, together with the previously cleared CTA, establishes a global Phase 1/2 clinical program for PM577a -- -- PM577a targets the H1069Q mutation in the ATP7B gene, the most p","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/23/3332566/0/en/Prime-Medicine-Announces-U-S-FDA-Clearance-of-Investigational-New-Drug-Application-for-PM577a-in-H1069Q-mutated-Wilson-Disease.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COPP","LABU","WD","BK4588","ICOP","CPER","CTA","BK4229","BK4585","COPJ","IND","BK4535","XME","UYM","CPXR","BK4195"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653747032","title":"YD Bio and EG BioMed Conclude Successful Exhibition at BIO Asia-Taiwan 2026, Highlighting Innovations in Ophthalmology, Oncology Diagnostics, and Clinical Services","url":"https://stock-news.laohu8.com/highlight/detail?id=2653747032","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653747032?lang=en_us&edition=fundamental","pubTime":"2026-07-23 20:00","pubTimestamp":1784808000,"startTime":"0","endTime":"0","summary":"Taipei, Taiwan, July  23, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and op","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/23/3332099/0/en/YD-Bio-and-EG-BioMed-Conclude-Successful-Exhibition-at-BIO-Asia-Taiwan-2026-Highlighting-Innovations-in-Ophthalmology-Oncology-Diagnostics-and-Clinical-Services.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4019","BK4585","LU0077335932.USD","LU0211331839.USD","IE0002270589.USD","EG","LNGR","LU1169589451.USD","IE00B19Z3581.USD","LU1169590202.USD","IE00B19Z3B42.SGD","BK4121","BIO","BK4588","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653667719","title":"Industrial Minerals calls crucial shareholder vote on Galleon Metals acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2653667719","media":"TIPRANKS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653667719?lang=en_us&edition=fundamental","pubTime":"2026-07-23 13:52","pubTimestamp":1784785964,"startTime":"0","endTime":"0","summary":"Industrial Minerals Limited ( ($AU:IND) ) has provided an update. Industrial Minerals Ltd has called a general meeting for 21 August 2026 in Pepper...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/industrial-minerals-calls-crucial-shareholder-vote-on-galleon-metals-acquisition?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/industrial-minerals-calls-crucial-shareholder-vote-on-galleon-metals-acquisition?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IND","RSBA","MRGR","PICK","BK4109","BK4535","MTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653270035","title":"Silo Pharma Advances Growth Platforms for AI Agent Commercialization and Lead PTSD Drug Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2653270035","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653270035?lang=en_us&edition=fundamental","pubTime":"2026-07-21 20:55","pubTimestamp":1784638500,"startTime":"0","endTime":"0","summary":"Silo continues to add technology assets as it expands its AI business and further develops its lead PTSD therapeutic candidate  AI agent platform prepares for commercial launch while SPC-15 regulatory","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/21/3330474/0/en/Silo-Pharma-Advances-Growth-Platforms-for-AI-Agent-Commercialization-and-Lead-PTSD-Drug-Program.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QTOC","VTHR","IND","CHAT","ARTY","AGIX","DBB","BK4135","AIPO","CNS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653277003","title":"Calidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value Drivers","url":"https://stock-news.laohu8.com/highlight/detail?id=2653277003","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653277003?lang=en_us&edition=fundamental","pubTime":"2026-07-21 20:00","pubTimestamp":1784635200,"startTime":"0","endTime":"0","summary":"Company receives positive pre-IND feedback from US FDA for CLD-401, indicating agreement on its current development strategy as it advances towards a first-in-human study; targeting dosing first patie","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/21/3330378/0/en/Calidi-Biotherapeutics-Provides-Mid-Year-Corporate-Update-and-Future-Key-Value-Drivers.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","LU0359202008.SGD","LU0359201612.USD","IND","BK4563","BK4108","LU2039709279.SGD","IE00BYQNZ168.SGD","LU0828238088.HKD","BK4552","BMS","LU1023057109.AUD","SG9999011746.SGD","TME","BK4548","LU0456842615.SGD","BK4509","BK4571","SITC","IE00B12V2V27.USD","01698","IE00BYTNYN87.SGD","BK4080","BK4531","BK4231","LU0509642566.USD","BK4526","LU0269904917.USD","BK4565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653627641","title":"Is HBM Holdings (SEHK:2142) Fully Valued After Its Asthma IND Approval?","url":"https://stock-news.laohu8.com/highlight/detail?id=2653627641","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653627641?lang=en_us&edition=fundamental","pubTime":"2026-07-21 18:16","pubTimestamp":1784629000,"startTime":"0","endTime":"0","summary":"HBM Holdings (SEHK:2142) is in focus after China’s National Medical Products Administration approved the Investigational New Drug application for HBM7575/SKB575, a long-acting bispecific antibody candidate for asthma co-developed with Kelun-Biotech.\nSee our latest analysis for HBM Holdings.\nThe IND approval appears to have reinforced interest in HBM Holdings, with the HK$11.96 share price supported by a 9.72% 1 month share price return and a very large 3 year total shareholder return, even...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2142/hbm-holdings-shares/news/is-hbm-holdings-sehk2142-fully-valued-after-its-asthma-ind-a","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2142/hbm-holdings-shares/news/is-hbm-holdings-sehk2142-fully-valued-after-its-asthma-ind-a","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DRAL","DRAM","BK1574","DRMY","RAM","BK1161","DISK","COPP","MUYY","BK1583","BK4168","MUZ","HBM","MIC","HBMX","MUU","IND","MUD","DCF","BK4588","MULL","02142","DRMP"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":6,"totalSize":200,"code":"91000000","status":"200"}]}}